Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Appears in Networks 2

In-Edges 5

a(CHEBI:methylglyoxal) increases p(MGI:Mapt, pmod(Ph, Ser, 199)) View Subject | View Object

Here, we found that MG could induce tau hyperphosphorylation at multiple AD-related sites in neuroblastoma 2a cells under maintaining normal cell viability. MG treatment increased the level of advanced glycation end products (AGEs) and the receptor of AGEs (RAGE). PubMed:22798221

Appears in Networks:

act(p(MGI:Gsk3b), ma(kin)) directlyIncreases p(MGI:Mapt, pmod(Ph, Ser, 199)) View Subject | View Object

Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation. PubMed:22798221

Appears in Networks:

act(p(MGI:Mapk14), ma(kin)) directlyIncreases p(MGI:Mapt, pmod(Ph, Ser, 199)) View Subject | View Object

Taken all together, we think that activation of GSK-3b and p38 should be responsible for MG-induced tau hyperphosphorylation. PubMed:22798221

Appears in Networks:

a(CHEBI:Nilvadipine) decreases p(MGI:Mapt, pmod(Ph, Ser, 199)) View Subject | View Object

Western blot analyses of brain homogenates show that (-)-nilvadipine significantly reduces Tau phosphorylation in AT8 (phosphorylated Ser-199/Ser-202/Thr-205) and PHF-1 (phosphorylated Ser-396/Ser-404) epitopes (Fig. 3). PubMed:25331948

Out-Edges 0

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.